AVB-001 is under clinical development by Avenge Bio and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AVB-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AVB-001 overview

AVB-001 is under development for the treatment of metastatic peritoneal cancers, ovarian cancer, fallopian tube cancer, mesothelioma and lung cancers. The therapeutic candidate comprises allogeneic genetically engineered cells expressing interleukin-2 (IL-2) in the tumor environment. It is administered through intraperitoneal route.

Avenge Bio overview

Avenge Bio focuses on Cell-Generated Immunotherapies to eradicate solid tumors. Avenge Bio is headquartered in Natick, Massachusetts, the US.

For a complete picture of AVB-001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.